ATE428803T1 - Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände - Google Patents

Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände

Info

Publication number
ATE428803T1
ATE428803T1 AT01270623T AT01270623T ATE428803T1 AT E428803 T1 ATE428803 T1 AT E428803T1 AT 01270623 T AT01270623 T AT 01270623T AT 01270623 T AT01270623 T AT 01270623T AT E428803 T1 ATE428803 T1 AT E428803T1
Authority
AT
Austria
Prior art keywords
expression
purinergem
preneoplastic
receptor
identify
Prior art date
Application number
AT01270623T
Other languages
English (en)
Inventor
Julian Barden
Michael Slater
Original Assignee
Biosceptre Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosceptre Pty Ltd filed Critical Biosceptre Pty Ltd
Application granted granted Critical
Publication of ATE428803T1 publication Critical patent/ATE428803T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01270623T 2000-12-11 2001-12-11 Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände ATE428803T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR2015A AUPR201500A0 (en) 2000-12-11 2000-12-11 Methods for identifying pre-neoplastic and neoplastic states in mammals
PCT/AU2001/001614 WO2002048395A1 (en) 2000-12-11 2001-12-11 P2y purinergic receptor expression for identifying preneoplastic and neoplastic states

Publications (1)

Publication Number Publication Date
ATE428803T1 true ATE428803T1 (de) 2009-05-15

Family

ID=3826050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01270623T ATE428803T1 (de) 2000-12-11 2001-12-11 Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände

Country Status (10)

Country Link
US (2) US20040067542A1 (de)
EP (1) EP1352085B1 (de)
JP (2) JP4334223B2 (de)
CN (1) CN100448486C (de)
AT (1) ATE428803T1 (de)
AU (1) AUPR201500A0 (de)
CA (1) CA2431362A1 (de)
DE (1) DE60138415D1 (de)
WO (1) WO2002048395A1 (de)
ZA (1) ZA200304853B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
ATE418565T1 (de) * 2001-01-17 2009-01-15 Intreat Pty Ltd Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden
FR2842424A1 (fr) * 2002-07-22 2004-01-23 Univ Paris 7 Denis Diderot Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques
US7601505B2 (en) * 2003-05-29 2009-10-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20090215711A1 (en) * 2004-04-30 2009-08-27 Sagres Discovery, Inc. Novel compositions and methods in cancer
KR20080003388A (ko) * 2005-04-01 2008-01-07 메드벳 싸이언스 피티와이. 리미티드 진단 및 치료 방법, 및 이에 유용한 제제
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
EP2201026B1 (de) 2007-09-14 2017-01-04 Biosceptre (Aust) Pty Ltd Neue p2x7-epitope
EP2201377B1 (de) 2007-09-14 2012-01-18 Biosceptre International Limited Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CA2729868C (en) 2008-07-04 2018-07-10 Biosceptre International Limited Anti- p2x7 peptides and epitopes
ES2557456T3 (es) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
ES2667003T3 (es) 2009-12-24 2018-05-09 Biosceptre (Aust) Pty Ltd Anticuerpos para receptores P2X7 oligoméricos no funcionales
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
CA2840251C (en) 2011-07-01 2023-09-12 Biosceptre International Limited Combination therapy of diseases that are associated with non-functional p2x7 receptor expression
CA2946669A1 (en) * 2014-05-02 2015-11-05 Medimmune Limited Ion channel modulators & uses thereof
JP7127021B2 (ja) 2016-10-21 2022-08-29 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 細胞傷害性粒子

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303338B1 (en) * 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
WO2000050458A1 (en) 1999-02-26 2000-08-31 Smithkline Beecham Corporation Cloning of a p2y-like 7tm receptor (axor17)
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) * 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
ATE418565T1 (de) * 2001-01-17 2009-01-15 Intreat Pty Ltd Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden

Also Published As

Publication number Publication date
US20040067542A1 (en) 2004-04-08
DE60138415D1 (de) 2009-05-28
CN1533440A (zh) 2004-09-29
WO2002048395A1 (en) 2002-06-20
AUPR201500A0 (en) 2001-01-11
EP1352085A4 (de) 2004-05-06
CA2431362A1 (en) 2002-06-20
JP2004520025A (ja) 2004-07-08
EP1352085A1 (de) 2003-10-15
US20080227122A1 (en) 2008-09-18
JP2009143933A (ja) 2009-07-02
EP1352085B1 (de) 2009-04-15
JP4334223B2 (ja) 2009-09-30
ZA200304853B (en) 2004-02-19
CN100448486C (zh) 2009-01-07

Similar Documents

Publication Publication Date Title
ATE428803T1 (de) Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände
CY1111042T1 (el) Μεθοδος απομονωσης βλαστικων κυτταρων
ATE321088T1 (de) Polysiloxanpolymere, verfahren zu ihrer herstellung und ihre verwendung
ATE412432T1 (de) Internalisierende erbb2 antikörper
DE69922038D1 (de) Herstellungsverfahren für retroreflektierende elemente mit erhöhter rückstreuung unter nassen bedingungen
TR200401348T4 (tr) Yapay elyaf halatların kontrol edilmesi için elektrik kontağı
ATE424560T1 (de) Marker für neuromyelitis optica
ES2185740T3 (es) Dispositivo de fijacion superficial.
DE69941093D1 (de) Vorrichtung zur umwandlung von kohlenwasserstoff-treibstoff-gas für brennstoffzellenanlage
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
ATE456799T1 (de) Verfahren zum identifizieren von präneoplastischen und neoplastischen stadien in säugern
ES2183349T3 (es) Dispersion de fibras de aramida y hojas de aramida.
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
DE69941090D1 (de) Verfahren zur schnellen kantendetektion, beständig gegen hohe intersymbolstörung
BR9703386A (pt) Células aviárias imortalizadas
ATE354582T1 (de) Klonierung und identifizierung des motilin- rezeptors
DE60011785D1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
SE0201750D0 (sv) Selective Chromophores
ATE253223T1 (de) Verfahren und materialien zur diagnose instabiler angina
ATE319839T1 (de) Verfahren zur verbesserung der transfektionseffizienz
ATE440993T1 (de) Mit calixarenen ausgerüstete textile materialien, verfahren zu ihrer herstellung und ihre verwendung
ATE280949T1 (de) Verfahren zur bestimmung der avidität von antikörpern
DE69535039D1 (de) Cytoplasmische tyrosin kinase
DK1360306T3 (da) DNA-sekvens af enzymet phospholipase A1 fra ciliate Tetrahymena og anvendelse heraf
AR016638A1 (es) Oligonucleotidos que permiten la identificacion de precursores de hormonas polipeptidas amidatadas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties